Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intestinal Permeability in Obesity (LEAKY GUT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02292121
Recruitment Status : Terminated (lack of surgical controls)
First Posted : November 17, 2014
Last Update Posted : January 20, 2021
Sponsor:
Collaborator:
Institute of Cardiometabolism and Nutrition, France
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:
In rodents, obesity is associated with changes in tight junctions' structure in small intestine, which impacts intestinal permeability and results in metabolic complications. Few data exist in human. We hypothesized that intestinal permeability is altered in obese subjects in comparison to lean subjects, linked to metabolic and inflammatory status and that these alterations are modified after gastric bypass.

Condition or disease Intervention/treatment Phase
Obesity Metabolic Diseases Nutrition Disorders Body Weight Procedure: Intestinal permeability Other: a solution of mannitol and lactitol Not Applicable

Detailed Description:

The regulation of the permeability of the intestinal barrier is essential in the molecular traffic between the lumen and the internal environment. It affects the absorption of nutrients and tolerance or immunization against foodborne non-self antigens that penetrate the barrier. In rodents, increased endotoxemia has been proposed as an important player in low-grade inflammation accompanying the development of obesity and metabolic disorders. In humans, the intestinal barrier function is altered in inflammatory bowel diseases (IBD, Crohn's disease, ulcerative colitis and celiac disease). The term "leaky gut" is used to describe a porous intestine with hyper-permeability associated with acute or chronic inflammatory diseases such as "systemic inflammatory response syndrome (SIRS),"acute inflammatory bowel disease (IBD for "inflammatory bowel disease").

Deficiencies of the barrier are also observed in extra-intestinal diseases (type-1 diabetes, food allergies, and autoimmune diseases). Impairments in tight junctions may precede clinical signs and constitute a risk factor for developing diseases or secondarily be altered and cause an increased entry of undesirable bacterial or nutritional antigens. The state of the intercellular tight junctions of the intestine controls the diffusion of molecules between cells. A deficiency of the intestinal barrier function is often associated with structural changes in the tight junctions resulting from loss of localization of protein or expression of genes and / or cellular signals such as ZO-1, occludin or tricellulin.

There are few studies about the condition of the intestinal barrier in the context of human obesity.

The objectives of our study are to :

  • compare intestinal permeability in obese subjects with non obese subjects and after gastric bypass.
  • search links between intestinal permeability and 1) metabolic and inflammatory bioclinical parameters 2) dietary profiles 3) microbiota

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Intestinal Permeability in Obesity of Intercellular Tight Junctions to Metabolic Complications
Actual Study Start Date : February 24, 2014
Actual Primary Completion Date : March 17, 2016
Actual Study Completion Date : March 17, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: obese group
40 obese subjects undergoing gastric bypass explored at baseline and 30 explored post-surgery at 6 months
Procedure: Intestinal permeability
5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.

Other: a solution of mannitol and lactitol
Active Comparator: non-obese control group (T1)
30 non-obese control subjects investigated for bio-clinical measures, IPT, zonulin, and LPS
Procedure: Intestinal permeability
5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.

Other: a solution of mannitol and lactitol
No Intervention: non obese control group undergoing a surgery (T2)
40 non-obese candidates to a surgery that gives access to surgical jejunal samples to measure the expression of tight junctions proteins



Primary Outcome Measures :
  1. urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) [ Time Frame: before gastric bypass and 6 months after ]
    Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in obese patients before gastric bypass and 6 months after


Secondary Outcome Measures :
  1. fasting zonulin serum concentrations [ Time Frame: before gastric bypass and 6 months after ]
    Measures of fasting zonulin serum concentrations in obese patients before gastric bypass and 6 months after

  2. LPS serum concentrations [ Time Frame: before gastric bypass and 6 months after ]
    Measures of LPS serum concentrations in obese patients before gastric bypass and 6 months after

  3. urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) [ Time Frame: inclusion and after one month ]
    Measures of urinary lactitol / mannitol ratio by an intestinal permeability test (IPT) in non-obese control subjects, performed twice with a one-month interval.

  4. surgical samples during surgery (sub-cutaneous and visceral adipose tissue) [ Time Frame: intraoperative ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria :

- Control subjects T1:

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 65 years old
  4. Fasting plasma triglycerides < 1.5 g/l (< 1.7 mmol/l)
  5. Fasting plasma total cholesterol < 2.5 g/l (< 6 mmol/l)
  6. fasting glycaemia < 5,5 mmol/l
  7. BMI <25kg/m² & >18 kg/m²
  8. Mean systolic blood pressure <140 mmHg and mean diastolic blood pressure < 90 mmHg.

Control subjects T2

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 70 years old
  4. IMC<25kg/m² et >18 kg/m²
  5. candidate to surgery giving access to jejunal samples

Obese subjects OB:

  1. Registered for social security
  2. Signed consent form
  3. male or female subject between 18 and 65 years old
  4. Candidate to bariatric surgery (bypass) with massive (IBMI >= 40 kg/m²) or severe obesity (BMI between 35 & 40 kg/m²) with at least one obesity-related comorbidity and with a stable weight (+/-5kg) for the last 3 months, after approval by a multidisciplinary team

Exclusion criteria :

- Control subjects T1:

  1. Subject with a history of vascular symptomatic disease in the last 6 months before selection.
  2. Subject receiving a treatment that can affect measured parameters
  3. Pregnancy
  4. Subject with acute or chronic disease that can affect measured parameters or to life-threatening. Including but not limited :

    1. Diabetic subjects
    2. Subject with kidney disease: nephrotic syndrome, chronic renal failure
    3. Subject having a gastrointestinal disorder or disease limiting intestinal absorption (celiac disease), bariatric surgery.
    4. Active inflammatory disease or a history of IBD
  5. Subject in a situation that, according to the investigator's opinion could interfere with an optimal participation to the study or constitute a particular risk to the subject
  6. Subject in an exclusion period after participating in another clinical trial
  7. Adult person subject to legal protection or unable to consent.
  8. Persons deprived of their liberty by judicial or administrative decision

Control subjects T2

  1. Subject with a history of symptomatic vascular disease (myocardial infarction, angina syndrome threat, surgical or endovascular surgery, stroke, lower limb arteritis symptomatic) of less than 6 months
  2. Subject with any acute or chronic disease which may influence the results of the study or to life-threatening. Including but not limiting:

    1. diabetic patients
    2. Subject with kidney disease: nephrotic syndrome, chronic renal failure and / or serum creatinine> 1.7 times the upper limit of the reference value
  3. Adult person subject to legal protection or unable to consent.
  4. Persons deprived of their liberty by judicial or administrative decision

Obese subjects candidates for surgery:

  1. Subject receiving treatment systemically or topically, which may interfere with the evaluation of the parameters studied (NSAIDs, antibiotics in the previous month)
  2. Any disease or psychosocial context making prolonged regular monitoring impossible, which also represents a contraindication for bariatric surgery.
  3. Adult person subject to legal protection or unable to consent.
  4. Persons deprived of their liberty by judicial or administrative decision

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02292121


Locations
Layout table for location information
France
Groupe Hospitalier Pitié-Salpêtrière
Paris, France, 75013
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Institute of Cardiometabolism and Nutrition, France
Investigators
Layout table for investigator information
Principal Investigator: Christine POITOU, MD, PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT02292121    
Other Study ID Numbers: P130402
First Posted: November 17, 2014    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021
Keywords provided by Assistance Publique - Hôpitaux de Paris:
Obesity
Intestinal permeability
Adipose tissue inflammation
Low grade systemic inflammation
Bariatric surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Metabolic Diseases
Nutrition Disorders
Body Weight
Overnutrition
Overweight
Mannitol
Lactitol
Diuretics, Osmotic
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Cathartics
Gastrointestinal Agents